-
公开(公告)号：WO2015147369A1
公开(公告)日：2015-10-01
申请号：PCT/KR2014/004108
申请日：2014-05-08
Applicant: 전북대학교산학협력단 , 전북대학교병원
IPC: A61K39/395 , A61K48/00 , A61K31/55 , A61K31/4725 , A61P35/00
CPC classification number: A61K31/55 , A23L33/10 , A23V2002/00 , A61K31/4709 , A61K31/713 , A61K45/06 , C07K16/40 , C07K2317/76 , C12N15/1137 , C12N2310/14 , A61K2300/00
Abstract: 본 발명은 SIRT2 억제제를 포함하는 약학적 조성물에 관한 것으로, 보다 상세하게는 SIRT2유전자의 발현 조절을 통해 패혈증에 의한 염증유발인자를 조절함으로써 신장염증을 완화시켜 신장손상을 억제하여 패혈증에 의한 신장 염증성 질환의 예방 또는 치료용 약학적 조성물, 시스플라틴과 함께 투여하였을 때 시스플라틴의 부작용인 신장 독성은 감소시키면서 항암 효능은 증진시키는 효과가 있는 암질환 예방 또는 치료용 약학적 조성물에 관한 것이다.
Abstract translation: 本发明涉及含有SIRT2抑制剂的药物组合物，更具体地说，涉及：由败血症引起的肾炎性疾病的预防或治疗药物组合物，通过调节SIRT2基因来控制脓毒病引起的炎症因子 表达，以减少肾脏炎症，从而预防肾损伤; 和用于预防或治疗癌症的药物组合物，当与顺铂一起施用时具有增加抗癌效力同时降低作为顺铂的副作用的肾毒性的作用。
-
公开(公告)号：KR1020100092570A
公开(公告)日：2010-08-23
申请号：KR1020090011741
申请日：2009-02-13
Applicant: 전북대학교산학협력단 , 한국식품연구원
IPC: A61K31/352 , A61P13/12
Abstract: PURPOSE: A composition containing genistein for preventing and treating inflammatory renal diseases is provided to suppress inflammatory renal diseases including acute renal injury. CONSTITUTION: A composition for preventing and treating inflammatory renal disease contains genistein. The disease is a disease cause by anticancer drug administration. The anticancer drug is cisplatin(cis-Diamminedichloroplatinum). Genistein reduces ICAM-1 and MCP-1 expression and suppresses NF-kappaB activation and ROS generation.
Abstract translation: 目的：提供含有用于预防和治疗炎症性肾病的染料木素的组合物，以抑制炎症性肾病，包括急性肾损伤。 构成：用于预防和治疗炎症性肾病的组合物含有染料木素。 该疾病是抗癌药物给药引起的疾病。 抗癌药物是顺铂（顺式二氨基氯铂）。 染料木黄酮降低ICAM-1和MCP-1表达，抑制NF-κB活化和ROS产生。
-
公开(公告)号：KR101622787B1
公开(公告)日：2016-05-20
申请号：KR1020140035993
申请日：2014-03-27
Applicant: 전북대학교산학협력단 , 전북대학교병원
IPC: A61K39/395 , A61K31/55 , A61K31/47 , A61K48/00 , A61P29/00
Abstract: 본발명은염증성질환의예방및 치료용약학적조성물에관한것으로, 보다상세하게는본 발명의 SIRT2억제제는 LPS-유도된염증유발인자인 CXCL2 및 CCL2의발현을억제함으로써신장염증을완화시켜신장손상을억제하여패혈증에의한신장염증성질환의예방및 치료할수 있는효과적인방법이될 수있다.
-
公开(公告)号：KR101336386B1
公开(公告)日：2013-12-04
申请号：KR1020110059046
申请日：2011-06-17
Applicant: 전북대학교산학협력단 , 전북대학교병원
Abstract: 본 발명은 과립구집락자극인자를 유효성분으로 포함하는 림프관 생성 유도제에 관한 것이다. 본 발명에서는 과립구집락자극인자가 사람 림프관내피 세포에서 세포 유주, 모세관 형성, 세포 증식, 림프관 발아를 유도하는 것을 확인하였고, 이러한 기작을 통하여 림프관을 생성한다. 또한 과립구집락자극인자는 사람 림프관내피 세포에서 맵 키나아제(MAP kinase)와 Akt 신호전달계를 통하여 림프관 생성을 유도할 수 있다.
-
公开(公告)号：KR1020120040041A
公开(公告)日：2012-04-26
申请号：KR1020100101549
申请日：2010-10-18
Applicant: 전북대학교산학협력단
CPC classification number: A61K38/1816 , C07K14/505
Abstract: PURPOSE: A lymphoduct generation inducer containing erythropoietin is provided to induce lymphduct through Akt/ERK pathway in human lymph vascular epithelial cells. CONSTITUTION: A lymphoduct generation inducer contains erythropoietin as an active ingredient. A composition for preventing or treating lymphedema contains erythropoietin as an active ingredient. A composition for preventing or treating lymphoduct loss or lymphopenia contains the erythropoietin as an active ingredient.
Abstract translation: 目的：提供含有促红细胞生成素的淋巴产生诱导物，通过人淋巴管上皮细胞中的Akt / ERK途径诱导淋巴细胞生成。 构成：产生淋巴产生的诱导物含有促红细胞生成素作为活性成分。 用于预防或治疗淋巴水肿的组合物含有促红细胞生成素作为活性成分。 用于预防或治疗淋巴细胞减少或淋巴细胞减少的组合物含有红细胞生成素作为活性成分。
-
Patent Agency Ranking
公开(公告)号：KR1020070006497A
公开(公告)日：2007-01-11
申请号：KR1020050061884
申请日：2005-07-08
Applicant: 전북대학교산학협력단
IPC: A61K31/4523 , A61K31/454 , A61K31/4535
CPC classification number: A61K31/4439 , A61K9/0012 , A61K9/0095 , A61K9/08 , A61K9/10 , A61K9/16 , A61K9/20 , A61K9/48 , A61K31/426
Abstract: A pharmaceutical composition comprising rosiglitazone is provided to be useful for decreasing renal disorders caused by sepsis, thereby being applied as a material useful for developing therapeutic agents effective for decreasing death rate and symptoms of a disease. The pharmaceutical composition for inhibiting renal disorders comprises rosiglitazone represented by the formula(1), a salt thereof or a derivative thereof. In the formula(1), each A and A' is independently Co N, R1 is C1-5 alkyl or H, and R2 is C1-5 alkyl, H, or hydroxy.
Abstract translation: 提供包含罗格列酮的药物组合物可用于减少由败血症引起的肾脏疾病，从而作为可用于开发有效降低死亡率和疾病症状的治疗剂的材料。 用于抑制肾脏疾病的药物组合物包括由式（1）表示的罗格列酮，其盐或其衍生物。 在式（1）中，A和A'各自独立地是Co N，R 1是C 1-5烷基或H，R 2是C 1-5烷基，H或羟基。
-
公开(公告)号：KR1020150113272A
公开(公告)日：2015-10-08
申请号：KR1020140036032
申请日：2014-03-27
Applicant: 전북대학교산학협력단 , 전북대학교병원
IPC: A61K39/395 , A61K31/55 , A61K31/4725 , A61K48/00 , A61P35/00
CPC classification number: A61K39/395 , A61K31/00 , A61K31/06 , A61K31/4725 , A61K31/55 , A61K48/00
Abstract: 본발명은항암제에의해유발되는신장독성질환의예방및 치료용약학적조성물에관한것으로, 보다상세하게는본 발명에따른 SIRT2억제제는시스플라틴과함께투여하였을때 세포사멸및 염증관련인자의발현을억제시킴으로써시스플라틴의부작용인신장독성은감소시키면서항암효능은증진시키는효과가있으므로, 암질환의예방및 치료를위한의약품및 암질환의예방및 개선을위한건강기능식품으로서유용하게이용될수 있다.
Abstract translation: 本发明涉及一种用于预防和治疗由抗癌剂引起的肾毒性的药物组合物，更具体地，本发明的无声信息调节剂2（SIRT2）抑制剂可有助于用于预防或治疗癌症的药物， 作为预防或治疗癌症的健康功能食品，由于具有通过抑制与顺铂一起施用的炎症相关因子的细胞凋亡和炎症相关因子的表达而具有增加抗癌功效而降低肾毒性的作用，这是顺铂的副作用。
-
公开(公告)号：KR1020120139311A
公开(公告)日：2012-12-27
申请号：KR1020110059046
申请日：2011-06-17
Applicant: 전북대학교산학협력단 , 전북대학교병원
CPC classification number: A61K38/193 , C07K14/535 , Y10S530/837
Abstract: PURPOSE: A lymphatic vascularization composition containing granulocyte-colony stimulating-factors is provided to induce capillarization, cell proliferation, and lymphatic sprout of human lymphatic vascular endothelial cells. CONSTITUTION: A lymphatic vascularization composition contains granulocyte-colony stimulating-factors as an active ingredient. The granulocyte-colony stimulating-factors include granulocyte macrophage colony stimulating factors(GM-CSF) and macrophage colony stimulating factors(MCSF). A composition for preventing or treating lymphedema contains the granulocyte-colony stimulating-factors as an active ingredient. A composition for preventing or treating lymphatic vessel loss or lymphopenia contains the granulocyte-colony stimulating-factors. An agent for enhancing ERK1/2 phosphorylation and Akt phosphorylation contains the granulocyte-colony stimulating-factors as an active ingredient.
Abstract translation: 目的：提供含有粒细胞集落刺激因子的淋巴管血管化组合物，以诱导人淋巴管血管内皮细胞的毛细血管化，细胞增殖和淋巴发芽。 构成：淋巴管血管化组合物含有粒细胞集落刺激因子作为活性成分。 粒细胞集落刺激因子包括粒细胞巨噬细胞集落刺激因子（GM-CSF）和巨噬细胞集落刺激因子（MCSF）。 用于预防或治疗淋巴水肿的组合物含有作为活性成分的粒细胞集落刺激因子。 用于预防或治疗淋巴管损失或淋巴细胞减少的组合物含有粒细胞集落刺激因子。 增强ERK1 / 2磷酸化和Akt磷酸化的药物含有粒细胞集落刺激因子作为活性成分。
-
公开(公告)号：KR100847751B1
公开(公告)日：2008-07-22
申请号：KR1020070042754
申请日：2007-05-02
Applicant: 전북대학교산학협력단
CPC classification number: A61K38/17 , Y10S514/866
Abstract: A pharmaceutical composition comprising COMP-Ang1(cartilage oligomeric matrix protein-angiopoietin-1) is provided to inhibit inflammation and regulate sugar and lipid metabolism, so that the composition is useful for treatment of diabetic nephropathy. A pharmaceutical composition for treatment of diabetic nephropathy comprises COMP-Ang1 and is administered orally or parenterally, wherein the COMP-Ang1 is prepared by replacing a coiled coil domain in a native angiopoietin-1 gene by cartilage oligomeric matrix protein, inserting the recombinant angiopoietin-1 gene into CHO(Chinese hamster ovary cell) cell line, and culturing the recombinant CHO cell line; the oral composition is formulated as tablet, pill, powder, granule, syrup, solution, suspension, emulsion or capsule, and the parenteral composition is formulated as injection, transrectal enteric preparations or transdermal preparations.
Abstract translation: 提供了包含COMP-Ang1（软骨低聚基质蛋白 - 血管生成素-1）的药物组合物以抑制炎症并调节糖和脂质代谢，使得该组合物可用于治疗糖尿病性肾病。 用于治疗糖尿病肾病的药物组合物包括COMP-Ang1并口服或非肠道给药，其中COMP-Ang1通过用软骨寡聚基质蛋白替代天然血管生成素-1基因中的卷曲螺旋结构域，将重组血管生成素 - 1基因转入CHO（中国仓鼠卵巢细胞）细胞系，培养重组CHO细胞系; 口服组合物配制成片剂，丸剂，粉剂，颗粒剂，糖浆剂，溶液剂，悬浮液，乳剂或胶囊剂，肠胃外组合物配制成注射剂，经直肠制剂或透皮制剂。
-
公开(公告)号：KR100794391B1
公开(公告)日：2008-01-15
申请号：KR1020070011205
申请日：2007-02-02
Applicant: 전북대학교산학협력단
CPC classification number: A61K38/39 , A61K9/0019 , A61K9/0053 , A61K9/2022
Abstract: A pharmaceutical composition comprising cartilage oligomeric matrix protein-angiopoietin-1 is provided to be used for treating the damage of endothelial cells and kidney fibrosis by protecting kidney endothelial cells. A pharmaceutical composition for treating unilateral ureteral obstruction comprises cartilage oligomeric matrix protein-angiopoietin-1. The composition is an oral formulation such as tablet, pill, powder, granule, syrup, liquid, suspension, emulsion and capsule or a non-oral formulation such as injection, transrectal formulation and transdermal formulation.
Abstract translation: 提供包含软骨低聚基质蛋白 - 血管生成素-1的药物组合物，用于通过保护肾内皮细胞来治疗内皮细胞和肾纤维化的损伤。 用于治疗单侧输尿管梗阻的药物组合物包括软骨低聚基质蛋白 - 血管生成素-1。 组合物是口服制剂，例如片剂，丸剂，粉剂，颗粒剂，糖浆剂，液体剂，悬浮剂，乳剂和胶囊剂或非口服制剂如注射剂，经直肠制剂和透皮制剂。
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.024 seconds)
